Article Figures & Data
Figures
- Figure 1.
Computed-tomographic (CT) scans of the abdomen before (left panel) and after (middle and right panels) sunitinib (SU) treatment. There are multiple liver metastases in the right lobe (top and middle panels, arrows), one of which was sensitive (top panel) and the other of which was resistant (middle panel) to sunitinib. Recurrent tumors were seen in the retroperitoneal space (bottom panel, arrowheads).
- Figure 2.
A: Macroscopic findings of the resected liver (left panel) and retroperitoneal gastrointestinal stromal tumors (GISTs) (right panel). B: Histological findings of the resected GISTs. Hematoxylin and eosin staining showed viable GIST cells as well as tumor cells with degenerative changes both in the liver (left panel) and retroperitoneum (right panel). C: DNA sequencing of the c-KIT gene at exon 13. Both liver (left panel) and retroperitoneal tumors (right panel) exhibited a T to C point mutation which resulted in a V654A amino acid alteration.
- Figure 3.
Post-operative computed-tomographic (CT) scans of the abdomen before (left two panels) and after (right two panels) sunitinib (SU) treatment. CT images show recurrent tumors in the retroperitoneal space, one of which was sensitive (upper panel, arrows) and the other of which was resistant (lower panel, arrowheads) to sunitinib.
